MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Tissue Engineering _ Stem Cells
Capricor Therapeutics, Inc. (NASDAQ: CAPR)*
Organization & Developments: Capricor
Parents
Capricor Therapeutics, Inc. (NASDAQ: CAPR)*
Children
*As well as CDC therapeutic programs
*Biotechnology company, engages in discovering, developing, and commercializing biotherapeutics for the treatment of heart diseases.
*It provides cardiac stem cell therapeutics to support or replace cells that have been damaged or lost due to chronic and acute heart disease.
*The company offers direct injection formulations and catheter infusible formulations of the cardiac derived cells (CDCs) for the treatment of myocardial infarction or heart attack
2024: Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
2024: Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission_seekingalpha.com
2024: Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off_ seekingalpha.com
2025: Capricor Plunges on FDA Rejection of DMD Cell Therapy
2025: Capricor signals readiness for deramiocel approval with $145M in cash and expanded commercial launch preparations
2025: Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential
2025: Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date
2025: Capricor: Further Value Unlocked With Priority Review Of Deramiocel
2025: Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term
2025: FDA rejects Capricor's Duchenne cell therapy
2026: Capricor: Stock Now Surging On Fresh BLA Updates - What Investors Must Know (NASDAQ:CAPR) | Seeking Alpha
Jumps
*Key People: Capricor
Finance & Acquisitions: Capricor